Last updated 6 days ago

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

150 patients around the world

Available in Mexico, United States

Eli Lilly and Company

2Research sites

150Patients around the world

This study is for people with

Obesity

To 17 Years

All Gender

: Have obesity, as defined by BMI equal to or above the 95th percentile for age and sex, on age- and sex-specific growth chart, or.
Have overweight, as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart, with at least 1 weight-related comorbidity.
Dyslipidemia.
Pre-hypertension.
Hypertension.
Nonalcoholic fatty liver disease.
Obstructive sleep apnea.
Prediabetes.
Documented preexisting condition of Type 2 Diabetes.
Participants with Type 2 Diabetes Mellitus (T2DM).
Have been treated with either diet and exercise alone or stable treatment with metformin for at least 90 days prior to screening and have a Hba1c<9.0%.

: Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight more than 5 kilogram (kg) (11 lbs.) within 90 days before screening irrespective of medical records.
Have Type 1 Diabetes.
Have taken within 90 days before screening or intend to start prescribed or over-the-counter medications, or alternative remedies including herbal or nutritional supplements, intended to promote body weight reduction.
Are prepubertal (Tanner stage 1).
Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple endocrine neoplasia (MEN) Syndrome Type 2.
Have a history of chronic or acute pancreatitis.
Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to
gastric bypass,
sleeve gastrectomy,
restrictive bariatric surgery, such as Lap-Band gastric banding, or
any other procedure intended to result in weight reduction.

Centro de Investigación Médica de Occidente, S.C. - Zapopan

Av. Ludwig Van Beethoven 5612, La Estancia, Zapopan, Jalisco

Investigación en Salud y Metabolismo S.C

Citadela 5901, Saucito, Chihuahua,

SponsorEli Lilly and Company

Conditions

Obesity

Requirements

To 17 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06075667